Know Cancer

forgot password

A Phase IB Study of Escalating Doses of REVLIMID in Association With R-CHOP (R2-CHOP) in the Treatment of B-cell Lymphoma

Phase 1/Phase 2
18 Years
70 Years
Open (Enrolling)
Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone B-Cell Lymphoma

Thank you

Trial Information

A Phase IB Study of Escalating Doses of REVLIMID in Association With R-CHOP (R2-CHOP) in the Treatment of B-cell Lymphoma

The study is a dose escalation study of lenalidomide (Revlimid) administered orally during
14 days in combination with fixed doses of rituximab (R), cyclophosphamide, doxorubicin,
vincristine and prednisone (CHOP) administered every 3 weeks (R-CHOP 21) in patients with
B-cell lymphoma.

Inclusion Criteria:

- Patients with one of the following B-cell Lymphoma, CD 20 positive:

- Mantle cell, Marginal zone, follicular

- Histological transformation from low grade to high grade

- Diffuse large B cell

- Aged from 18 to 70 years

- WHO performance status 0, 1 or 2

- Signed inform consent

- Life expectancy of ≥ 90 days (3 months).

- Females of childbearing potential (FCBP)† must have a negative serum or urine
pregnancy test with a sensitivity of at least 25 mIU/mL not more than 3 days from the
start of study drug and must either commit to continued abstinence from heterosexual
intercourse or begin one acceptable method of birth control, at least 4 weeks before
she starts taking lenalidomide. FCBP must also agree to monthly pregnancy testing
and must be counseled at a minimum of every 4 weeks about pregnancy precautions and
risks of fetal exposure.

- Men must agree not to father a child and agree to use a condom if his partner is of
child bearing potential. Men must also be counseled at a minimum of every 4 weeks
about pregnancy precautions and risks of fetal exposure.

- † A female patient is considered to have childbearing potential unless she meets
at least one of the following criteria 1) Age > 50 years and naturally
amenorrhoeic for > 1 year (amenorrhoea following cancer therapy does not rule
out childbearing potential); or 2) Premature ovarian failure confirmed by a
specialist gynaecologist or 3) Previous bilateral salpingo-oophorectomy, or
hysterectomy, or 4) XY genotype, turner syndrome, uterine agenesis.

Exclusion Criteria:

- Previous treatment with immunotherapy or chemotherapy except:

- Chlorambucil or Cyclophosphamide per os alone during less than 6 months, if
stopped more than one year before inclusion

- Rituximab alone during less than three months, if stopped more than one year
before inclusion

- Previous radiotherapy except if localized to one lymph node area

- Other type of lymphomas: Burkitt, T cell, lymphocytic, CD 20 negative

- Central nervous system or meningeal involvement

- Contraindication to any drug contained in the chemotherapy regimen

- HIV disease, active hepatitis B or C

- Any serious active disease or co-morbid medical condition (according to
investigator's decision)

- Any of the following laboratory abnormalities :

- Absolute neutrophil count (ANC) < 1,500 cells/mm3 (1.5 x 109/L).

- Platelet count < 100,000/mm3 (100 x 109/L).

- Serum SGOT/AST or SGPT/ALT 5.0 x upper limit of normal (ULN).

- Serum total bilirubin > 2.0 mg/dL (34 µmol/L), except in case of hemolytic

- Calculated creatinine clearance (Cockcroft-Gault formula) of < 50 mL /min

- Prior history of malignancies other than lymphoma (except for basal cell or squamous
cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the
subject has been free of the disease for ≥ 3 years

- Any serious medical condition, laboratory abnormality, or psychiatric illness that
would prevent the subject from signing the informed consent form.

- Pregnant or lactating females.

- Prior ≥ Grade 3 allergic reaction/hypersensitivity to thalidomide.

- Prior ≥ Grade 3 rash or any desquamating (blistering) rash while taking thalidomide.

- Subjects with ≥ Grade 2 neuropathy.

- Prior use of lenalidomide.

- Use of any standard or experimental anti-cancer drug therapy within 28 days of the
initiation (Day 1) of study drug therapy.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Incidence of Dose Limiting Toxicities

Outcome Time Frame:

42 days

Safety Issue:


Principal Investigator

Hervé TILLY, Prof

Investigator Role:

Principal Investigator

Investigator Affiliation:

Lymphoma Study Association


France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Study ID:




Start Date:

January 2009

Completion Date:

January 2012

Related Keywords:

  • Lymphoma, Large B-Cell, Diffuse
  • Follicular Lymphoma
  • Mantle Cell Lymphoma
  • Marginal Zone B-Cell Lymphoma
  • lymphoma
  • lenalidomide
  • gela
  • Lymphoma
  • Lymphoma, Follicular
  • Lymphoma, B-Cell
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, B-Cell, Marginal Zone
  • Lymphoma, Mantle-Cell